SBIR/STTR Research Award

Evaluating the Safety and Efficacy of Cartilage Regeneration with Tunable Inflammation Resistance

Award identifier a6ce003663bee20832849855406a5c877225e78a1420863ba939f5a9fc7fec91Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Cytex Therapeutics, Inc.
Proposal award date
2018-09-18
Contract end date
2019-08-31
UEI
G9RMDCWJYGL3
Solicitation number
PA17-302
Topic code
NIAMS

Research abstract

Abstract The repair of large cartilage lesionswhich often lead to osteoarthritisOAremains a significant clinical problem with few good treatment optionsPrevious work at Cytex has focused on the developing of aD woven textile scaffold for cartilage repairdesigned to function immediately upon implantationwhile encouraging cell ingrowthproliferationand subsequent tissue developmentBy combining this proprietaryD woven implant with adiposederived stem cellsASCswe have demonstrated the ability to generate largeanatomically shaped cartilage constructs with biomimetic mechanical propertiesNeverthelessfor a cell based cartilage therapy to be successful in an OA patientit must withstand the catabolic effects of joint inflammationwhich are mediated by the action of elevated levels of pro inflammatory cytokines such as interleukinILand tumor necrosis factor alphaTNFaHoweverbecause of the pleiotropic role of ILand TNFa in vivolong term sustained anticytokine therapy is not recommendedThereforethe objective of this project is to evaluate the safety and efficacy of an engineered functional cartilage replacement capable of protecting itself from OA inflammation by producing an anti cytokine therapyTo this endwe propose to use an inflammation responsive promoter to drive expression of therapeutic factorsspecificallyILreceptor antagonist and soluble TNF receptorThis will create an auto regulated system in which cells express and secrete anti cytokine proteins only when inflammatory signaling is presentIn Aimwe will modulate the lentiviral transduction process in an effort to minimize the risk of genetic side effects in our biomimetic cartilage implantOur goal is to minimize the number of viral integration events in each cellwhile maintaining a high transduction efficiencyso that the ASCs in our implant can effectively deliver the anti cytokine therapyIn Aimour engineered cartilage will be implanted subcutaneously in an inflammatory mouse model to test the construct s ability to sense and prevent catabolic degradationSerum will be collected from the mice longitudinally to measure the levels of inflammatory cytokines present in the modelas well as the levels of anti cytokine therapeutics produced by our implant in direct response to the inflammatory cytokinesAt sacrificethe cartilage constructs will be excised and assessed histologicallybiochemicallyand biomechanically to quantify any degradative changes that have occurred in the tissueAdditionallyall major organ systems of the mice will be examined histologically to assess the safety of implanting transduced cells and utilizing anti cytokine therapyThis proposal addresses the clinical need for large functional cartilage replacements that can thrive in an inflamed osteoarthritic jointand couldas a consequencehave a major impact on the treatment paradigm of this disease OsteoarthritisOAis one of the leading causes of disability in the worldand while a totaljoint replacement is a highly successful treatment option for patients older thanyearsof agethere areunfortunatelyno good current treatment options for the young patientpopulation suffering from this diseaseThe objective of this study is to further the developmentof abiosyntheticimplant that can both replace diseased cartilage and also detect and respond todegradative inflammation to protect the long term integrity of the implant

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

22 SBIR/STTR records share this UEI (2007–2023). Reported award amounts total $18,271,228. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.